Subscribe
(L-R): Monika Rai, Stephen Murnaghan, Jocelyn Ram, Kip Bodi
8 May 2025NewsAmericasMarisa Woutersen

LSPN: Counsel grapple with AI’s impact on training and critical thinking

Experts at LSPN Boston stress the need for cross-disciplinary teams and careful training as artificial intelligence software becomes mainstream, reports Marisa Woutersen.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025   Wilson Sonsini, Desmarais, and Wolf Greenfield were among the winners at the inaugural LSPN Awards USA 2025 in Boston, which celebrated excellence in life sciences IP across 20 categories.
Americas
LSPN: Trump's policy storm causing chaos and confusion
7 May 2025   In just 100 days, the Trump administration has issued a record-breaking 90 executive orders—triggering operational uncertainty, staffing upheaval, and growing delays at the US Patent and Trademark Office, hears Marisa Woutersen at LSPN in Boston.
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025   The ‘Wands factors’ are extending patent litigation—allowing functionally defined claims to survive longer than expected, hears Marisa Woutersen in Boston.


Editor's picks

LSPN: In-house ‘chess game’ is the same, but the rules have changed
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

Editor's picks

Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025   Wilson Sonsini, Desmarais, and Wolf Greenfield were among the winners at the inaugural LSPN Awards USA 2025 in Boston, which celebrated excellence in life sciences IP across 20 categories.
Americas
LSPN: Trump's policy storm causing chaos and confusion
7 May 2025   In just 100 days, the Trump administration has issued a record-breaking 90 executive orders—triggering operational uncertainty, staffing upheaval, and growing delays at the US Patent and Trademark Office, hears Marisa Woutersen at LSPN in Boston.
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025   The ‘Wands factors’ are extending patent litigation—allowing functionally defined claims to survive longer than expected, hears Marisa Woutersen in Boston.

More on this story

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025   Wilson Sonsini, Desmarais, and Wolf Greenfield were among the winners at the inaugural LSPN Awards USA 2025 in Boston, which celebrated excellence in life sciences IP across 20 categories.
Americas
LSPN: Trump's policy storm causing chaos and confusion
7 May 2025   In just 100 days, the Trump administration has issued a record-breaking 90 executive orders—triggering operational uncertainty, staffing upheaval, and growing delays at the US Patent and Trademark Office, hears Marisa Woutersen at LSPN in Boston.
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025   The ‘Wands factors’ are extending patent litigation—allowing functionally defined claims to survive longer than expected, hears Marisa Woutersen in Boston.

More features

Fed Circ refuses to stay Novartis feud with MSN over Entresto
Moderna entities must face infringement suits, UPC rules
Baker McKenzie adds London partner with ‘enviable’ expertise
‘Keep calm and carry on’: UK+ regime stays post-Brexit
As AI shakes up pharma and biotech, can patent law keep up?
UK court clears the way for Amgen and Samsung to launch biosimilars
SK Bioscience prevails over Pfizer in pneumococcal vaccine dispute
‘It’s going to be very different’: INTA CEO shares London meeting plans